⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17014926 | 0.85 | — | — | |
| SCHEMBL23270889 | 0.83 | — | — | |
| SCHEMBL18593119 | 0.81 | TSHR (0.43) | — | |
| Dimethyl Succinate SCHEMBL31517013 | 0.80 | TSHR (0.56) | — | |
| SCHEMBL2600114 | 0.78 | — | — | |
| SCHEMBL13430572 | 0.78 | — | — | |
| SCHEMBL13916168 | 0.77 | — | — | |
| SCHEMBL1335930 | 0.75 | — | — | |
| SCHEMBL16807356 | 0.75 | — | — | |
| SCHEMBL18863908 | 0.75 | TSHR (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | disclosed |
| US-20180258085-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| US-9975890-B2 | Bicyclic AZA compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-05-22 | — | — | US | disclosed |
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9669013-B2 | Bicyclic aza compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-06 | — | — | US | disclosed |
| EP-2897948-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2016-08-31 | — | — | EP | disclosed |
| US-20160128996-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-9266857-B2 | Bicyclic AZA compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-2897948-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014045031-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-03-27 | — | — | WO | disclosed |
| US-7820666-B2 | Tetrahydrotriazolopyrazine derivatives and uses thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080280913-A1 | TETRAHYDROTRIAZOLOPYRAZINE DERIVATIVES AND USES THEREOF | CONCERT PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |